Galactose-Decorated Liver Tumor-Specific Nanoliposomes Incorporating Selective BRD4-Targeted PROTAC for Hepatocellular Carcinoma Therapy

Researchers suggested that galactosylated nanoliposomes incorporating ARV-825 was a novel actively targeted PROTAC-based nanotherapeutic approach for hepatocellular carcinoma.